Eagle Pharmaceuticals Inc, Teva deal

Eagle granted Teva exclusive, U.S. rights to commercialization EP-3102 to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL). EP-3102 is a ready-to-dilute formulation of bendamustine, an alkylating agent, requiring 50 mL saline or a mixture of sodium chloride and dextrose. Eagle submitted an NDA to FDA for the product to treat patients with CLL and with indolent B cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The company requested Priority Review for the NDA. ...